Skip to main content

Table 5 Secondary endpoints - pain over the last 24 hours and global patient assessment on disease activity evaluated at each visit on a VAS (100 mm)

From: Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial

 

N

Pain (VAS)

P value

Disease activity

P value

V1

22

49.41 ± 24.94

ns

60.00 ± 22.67

ns

V2

22

50.95 ± 23.85

ns

58.32 ± 20.37

ns

V3

21

44.52 ± 27.41

ns

48.71 ± 27.37

ns

V4

20

42.20 ± 26.33

ns

42.70 ± 25.82

ns

V5

20

39.20 ± 28.96

ns

38.85 ± 27.66

0.0047*

  1. *p value versus V1. Data are mean ± sd and were analyzed with Student t-test. V1: first visit, at the time of selection; V2: visit after 7 days of treatment; V3: visit after 14 days of treatment; V4: visit after 28 days of treatment; V5: visit after 84 days of treatment.
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us